Core Viewpoint - Universal Ibogaine Inc. is currently under a Management Cease Trade Order (MCTO) due to delays in filing its annual audited financial statements and is providing bi-weekly updates on its default status [1][3][5]. Group 1: Default Status and Compliance - The company announced a delay in filing its annual audited financial statements for the year ended July 31, 2025, past the deadline of November 28, 2025 [2]. - A management cease trade order was granted by the Alberta Securities Commission on December 4, 2025, requiring ongoing bi-weekly default status reports [3]. - The company intends to comply with alternative information guidelines and will continue to disclose material information regarding its business activities [5]. Group 2: Restructuring Process - There have been no material changes in the company's restructuring process since the last update, and it continues to fulfill its reporting obligations [6]. - The company has temporarily closed its Kelburn Recovery Centre and is exploring financing options, including the potential sale of the property [7]. - A portion of the proceeds from any sale is intended to be used for completing the audit process and repaying outstanding convertible debt of $726,500 [13]. Group 3: Company Overview - Universal Ibogaine Inc. aims to transform addiction treatment using medicalized ibogaine and plans to conduct a clinical trial focused on opioid use disorder [9].

  Calgary, AB – TheNewswire - December 18, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, provides the following initial bi-weekly default status report update:Management Cease Trade Order (“MCTO”)Further to the Company’s prior news releases (dated November 25, 2025), the Company is providing this bi-weekly default status report (the “Default Status Report”) in accordance with National Policy ...

Core Viewpoint - Universal Ibogaine Inc. is seeking a Management Cease Trade Order (MCTO) from the Alberta Securities Commission due to delays in filing required financial documents, which is attributed to limited financial resources and ongoing restructuring efforts [1][3][4] Group 1: MCTO Application - The company has applied for a temporary MCTO under National Policy 12-203, which would restrict trading of its securities by the CEO and the currently vacant CFO until the MCTO is revoked or the required filings are completed [1][2] - There is no guarantee that the MCTO will be granted, but the general public can still trade the company's common shares during this period [2] Group 2: Required Filings - The company failed to file its audited consolidated financial statements for the year ended July 31, 2025, along with the related management's discussion and analysis and CEO and CFO certificates by the November 28, 2025 deadline [3] - The delay is due to limited financial resources affecting the completion of the audit, and the company aims to rectify this situation and complete the required filings by January 30, 2026 [4] Group 3: Compliance and Reporting - Until the required filings are completed, the company will adhere to alternative information guidelines set out in NP 12-203, which includes issuing bi-weekly default status reports via news releases [5] Group 4: Company Overview - Universal Ibogaine Inc. is focused on transforming addiction treatment using medicalized ibogaine, with plans for a Canadian clinical trial targeting opioid use disorder and future global licensing agreements [7]

Core Insights - Universal Ibogaine Inc. has temporarily closed its Kelburn Recovery Centre as part of a restructuring process aimed at exploring financing options, including potential sale or leasing of the property [1][2] - The company remains focused on its primary mission to obtain approval for ibogaine use through a planned clinical trial targeting opioid use disorder, with intentions to expand treatment protocols globally [2][3] Company Overview - Universal Ibogaine Inc. is a life sciences company dedicated to transforming addiction treatment using medicalized ibogaine, with a focus on opioid use disorder [3] - The company aims to revolutionize addiction treatment and improve the lives of individuals and families affected by addiction through planned clinical trials and future licensing agreements [3]

Group 1 - Universal Ibogaine Inc. has undergone a transition in its Board of Directors, with several members resigning to strengthen the company's foundation for future growth [1][2] - The current Board members include Eric Hrimech, Nia Killebrew, Tony Wagner, James Duncan, and Nick Karos, as the company prepares to submit its clinical trial application to Health Canada by the end of November 2025 [2] - The company aims to transform addiction treatment through medicalized ibogaine, focusing on opioid use disorder, and plans to develop a holistic addiction treatment protocol at its Kelburn Recovery Centre [4] Group 2 - Universal Ibogaine Inc. is positioned as a life sciences company with a mission to revolutionize addiction treatment and improve the lives of individuals and families affected by addiction [4] - The company is planning future licensing agreements to utilize its treatment protocol globally, indicating a strategic approach to expand its market reach [4]

Core Insights - Universal Ibogaine Inc. has appointed two new Directors, Nia Killebrew and Tony Wagner, to its Board effective August 28, 2025, filling a previously vacant position [1][2] - The Annual Meeting of Shareholders (AGM) is scheduled for September 4, 2025, where current Board member Dean Koumontzis will not stand for re-election [2] Company Overview - Universal Ibogaine Inc. is focused on transforming addiction treatment through medicalized ibogaine, with plans for a Canadian clinical trial targeting opioid use disorder [4] - The company is developing a holistic addiction treatment protocol at its Kelburn Recovery Centre, which aims to enhance the effectiveness of the ibogaine detox protocol [4]

Company Overview - Universal Ibogaine Inc. is a life sciences company focused on researching and delivering medicalized ibogaine-centered addiction care [4] - The company aims to transform addiction treatment through a planned Canadian clinical trial targeting opioid use disorder and intends to utilize this treatment protocol globally via future licensing agreements [4] Recent Developments - Ken Cranwill has resigned from the Board of Directors to focus on other business ventures, with the company expressing gratitude for his service over the past year [1] - The company has received approval from the TSX Venture Exchange to settle $106,200 in consulting fees owed to CEO Nick Karos by issuing 4,248,000 common shares at a price of $0.025 per share [2] - Following the share issuance, Universal Ibogaine will have a total of 312,858,516 common shares outstanding [2] Future Plans - The company is concurrently developing a holistic addiction treatment protocol at its Kelburn Recovery Centre, which, when combined with the ibogaine detox protocol, aims to revolutionize addiction treatment and improve the lives of affected individuals and families [4]